Actavis seeks approval for Alzheimer’s patch
PARSIPPANY, N.J. — Actavis is challenging Novartis’ patent on a patch used to treat Alzheimer’s disease, Actavis said.
The generic drug maker said it had filed with the Food and Drug Administration an amendment to its regulatory application for rivastigmine transdermal system to include the 13.3 mg-per-24-hours dosage strength, a generic version of Novartis’ Exelon. Novartis filed suit against Actavis on Thursday in the U.S. District Court for the District of Delaware seeking to prevent commercialization of the generic version.
In November 2011, the company, then known as Watson Pharmaceuticals, filed an application with the FDA for a generic version of Exelon in the 4.6 mg-per-24-hours and 9.5 mg-per-24-hours strengths. Novartis sued to prevent commercialization of those strengths separately.
Actavis said it was likely the first company to file applications for generic versions of Exelon, which would entitle it to 180 days of market exclusivity in which to compete directly against the branded version. Exelon had sales of about $521 million during the 12-month period that ended in January, according to IMS Health.
Teva CFO to present at Barclays conference
JERUSALEM — Teva Pharmaceutical Industries will sponsor a live audio webcast at the 2013 Barclays Global Healthcare Conference on Thursday, the Israeli generic drug maker said Tuesday.
Teva CFO Eyal Desheh will present. The company is one of several scheduled to present at the conference this week.
The webcast will be available on the company’s website and is scheduled to begin at 9:30 Eastern time. An archive of the webcast will be available afterward.
Diplomat Specialty Pharmacy CEO Phil Hagerman joins NASP board
TAMPA, Fla. — Diplomat Specialty Pharmacy CEO Phil Hagerman has joined the board of directors of the National Association of Specialty Pharmacy, the group said Tuesday.
The NASP also noted that Diplomat had joined it as a founding member. Diplomat is the largest privately-owned specialty pharmacy in the country, with revenues exceeding $1.1 billion in 2012.
"Specialty pharmacy is a rapidly growing sector of the pharmacy industry, and I am honored to serve on the board of an organization dedicated to building partnerships that will identify challenges and advance our common goals," Hagerman said. "Collaboration is essential to improving the care that our patients need and deserve."